ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Inflammation"

  • Abstract Number: 1830 • ACR Convergence 2024

    Single-cell RNA Sequencing Profiling of Very Early-Stage Systemic Sclerosis Skin Reveals a Fibroblast Pro-inflammatory Gene Signature and Keratinocyte Dysregulation

    Lumeng Li1, Elena Pachera2, Rucsandra Dobrota3, Kristina Bürki1, Carina Mihai3, Muriel Elhai4, Laura Much1, Astrid Hofman1, Pietro Bearzi5, Sophie Wagner6, Sarah Lötscher7, Anna-Maria Hoffmann-Vold8 and Oliver Distler9, 1Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, 2University Hospital Zurich, Zurich, Switzerland, 3University Hospital Zurich, University of Zurich, Zurich, Switzerland, 4University Hospital zurich, Zürich, Switzerland, 5Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Schlieren, Switzerland, 6University of Zurich, Schlieren, Switzerland, 7Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Zurich, Switzerland, 8Oslo University Hospital, Oslo, Norway, 9Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, Zurich, Switzerland

    Background/Purpose: The poor prognosis of patients with systemic sclerosis (SSc) underscores the need to prevent disease onset and irreversible organ damage. This study aims to…
  • Abstract Number: 2042 • ACR Convergence 2024

    Overview of Lung Manifestations in Sarcoidosis and Various Treatment Approaches at a University Center

    Aleeza Qamar1, Upasana Agrawal2, Karan Sachdeva3, Zara Hassan4, Alex Zamora1, Syeda Nida5, Sarwat Umer1, Samina Hayat1 and Kinza Muzaffar6, 1LSU Health-Shreveport, Shreveport, 2LSU Health, Shreveport, Shreveport, LA, 3Louisiana state university health shreveport LA, Shreveport, 4Louisiana State University Health Sciences, Shreveport, LA, 5LSU Healh-Shreveport, Shreveport, 6LSU HEALTH SHREVEPORT, SHREVEPORT, LA

    Background/Purpose: Sarcoidosis is a disease occurring in the form of non-caseating granulomas, with unclear etiology and multi-system manifestations. Pulmonary involvement in sarcoidosis is a cardinal…
  • Abstract Number: 2562 • ACR Convergence 2024

    Efficacy and Safety of Tocilizumab in the Treatment of Chronic Inflammatory Forms of CPPD: Retrospective Study of 55 Cases

    Sophie Carrabin1, Margaux Houze2, Charlotte Jauffret3, Thomas Bardin4, Hang Korng Ea4, Frédéric Lioté4, Pascal Richette5, Tristan Pascart2 and Augustin Latourte6, 1Hôpital Lariboisière APHP.Nord, Paris, Paris, France, 2Lille Catholic University, Lille, France, 3Lille Catholic University, Lille, Nord-Pas-de-Calais, France, 4Hôpital Lariboisière APHP.Nord, Paris, France, 5Lariboisière Hospital, Paris, France, 6AP-HP, Paris, France

    Background/Purpose: Calcium pyrophosphate deposition disease (CPPD) is a heterogeneous disease that can manifest as acute or chronic arthritis. Treatment options for chronic forms of the…
  • Abstract Number: 0024 • ACR Convergence 2024

    Trans-Signaling by Soluble CD14 Sensitizes Chondrocytes to Lipopolysaccharide Stimuli, Increasing Chondrocyte Inflammatory Responses

    Anna E. Rapp, Baofeng Hu and Carla Scanzello, University of Pennsylvania, Philadelphia, PA

    Background/Purpose: The understanding of osteoarthritis (OA) has evolved significantly over the past decade. Recently attention is being drawn to the role of pattern-recognition receptor (PRR)…
  • Abstract Number: 0246 • ACR Convergence 2024

    Selectively Targeting TRBV11-2+ T Cells in Multisystem Inflammatory Syndrome in Children (MIS-C) Using Bispecific T Cell-Engaging Antibodies

    Elana Shaw, Stephanie Glavaris, Brian Mog, Alexander Pearlman, Sarah DiNapoli, Jin Liu, Kyle J. Kaeo, Kenneth W. Kinzler, Chetan Bettegowda, Shibin Zhou, Bert Vogelstein, Suman Paul and Maximilian F. Konig, The Johns Hopkins University School of Medicine, Baltimore, MD

    Background/Purpose: Multisystem Inflammatory Syndrome in Children (MIS-C) is a rare but potentially deadly immune complication after infection with SARS-CoV-2. In patients with MIS-C, a striking…
  • Abstract Number: 0563 • ACR Convergence 2024

    Clinical Features of Patients with SpA, with or Without IBD: Results from the METEOR Cohort

    Manouk de hOoge1, Pedro M. Machado2, Sytske Anne Bergstra3, Maxime Dougados4, Clementina López Medina5, Victoria Navarro Compán6, Diego Benavent7, Denis Poddubnyy8, Levent kilic9, Philippe Carron10, Dirk Elewaut11, Filip Van den Bosch12 and Gaelle Varkas12, 1Dept. of Internal Medicine and Pediatrics, Ghent University, Ghent, Belgium, 2Department of Rheumatology, University College London Hospitals NHS Foundation Trust; and Department of Rheumatology, Northwick Park Hospital, London North West University Healthcare NHS Trust; and Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, United Kingdom, 3LUMC, Leiden, Netherlands, 4Rheumatology Department, Cochin Hospital and Clinical Epidemiology and Biostatistics, University of Paris, INSERM (U1153), Paris, France, 5Reina Sofia University Hospital, Cordoba, Spain, 6La Paz University Hospital, Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain, 7Rheumatology Department, Hospital Universitari de Bellvitge, Barcelona, Spain, CAMBRILS, Spain, 8Charite-Universitatsmedizin Berlin, Berlin, Germany, 9Dept. of Rheumatology, Hacettepe University, Ankara, Turkey, Ankara, Turkey, 10UZ Gent, Gent, Belgium, 11Ghent University and VIB Center for Inflammation Research, Ghent, Belgium, 12Ghent University Hospital, Ghent, Belgium

    Background/Purpose: To investigate clinical features of SpA patients with and without IBD, identifying the patient group that would benefit from initiating therapy with efficacy in…
  • Abstract Number: 0878 • ACR Convergence 2024

    YY1 a Potential Modulator of IL17/IL23 Axis in Psoriasis Disease

    vinod kumar, Tammana Sharma, Rahul Mahajan, Tarun Narang, Sunil Dogra and Sanjeev handa, PGIMER, Chandigarh, Chandigarh, India

    Background/Purpose: Psoriasis is an inflammatory skin disease that progresses and worsens if left unattended. IL17 plays a pivotal role as a pathogenic trigger. Despite Th17…
  • Abstract Number: 0991 • ACR Convergence 2024

    Comparing the Prevalence of Sarcoidosis in Canadian Rural, Urban, and Farming Populations

    Varinder Hans1, Don Voaklander1, C. Allyson Jones2 and Elaine Yacyshyn2, 1University of Alberta, Edmonton, Canada, 2University of Alberta, Edmonton, AB, Canada

    Background/Purpose: Sarcoidosis is a granulomatous inflammatory response thought to be due to a dysregulated immune response to environmental antigens.1 The prevalence of sarcoidosis varies geographically.…
  • Abstract Number: 1579 • ACR Convergence 2024

    Exploring the Cardiovascular Complications of Pulmonary Arterial Hypertension in Individuals with Systemic Sclerosis

    Omar Mourad1, Saif Abu Baker1, Georges Khattar2, Jennifer Jdaidani3, Khalil El-Gharib3 and Ahmad Mustafa3, 1Staten Island University Hospital- Northwell Health, Staten Island, NY, 2Staten Island University Hospital, Staten Island, NY, 3Staten Island University Hospital- Northwell Health, Staten Island

    Background/Purpose: Systemic sclerosis (SS) is a complex autoimmune rheumatic disease characterized by immune-mediated activation of both innate and adaptive immunity. Pulmonary involvement, specifically pulmonary arterial…
  • Abstract Number: 1838 • ACR Convergence 2024

    M5542: A Potent CD80, CD86, and OX40L Antagonist Fusion Molecule for the Treatment of Autoimmune Diseases

    Michelle Downing1, Ling Zhang1, Aditee Desphpande1, Hong Zhang1, Ohad Tarcic2, Mira toister-achituv2, Alec Gross3, Gang Chen3 and Chia Chi Sun1, 1EMD Serono Research and Development Institute, Inc., Billerica, MA, 2Inter-lab Ltd, Merck KGaA, Yavne, Israel, 3EMD Serono Reserch and Development Institute, Inc, Billerica, MA

    Background/Purpose: Overactive adaptive immune responses contribute to many autoimmune diseases such as systemic lupus erythematosus (SLE). Chronically activated autoreactive T-effector cells play a pivotal role…
  • Abstract Number: 2078 • ACR Convergence 2024

    Increased RAGE Expression in Myositis

    Madison King1, Rita Spathis2, Elizabeth Bagley1 and Melissa Morales3, 1Binghamton University, Johnson City, NY, 2Binghamton University School of Pharmacy and Pharmaceutical Sciences, Johnson City, NY, 3SUNY Binghamton, Johnson City, NY

    Background/Purpose: Myositis is a broad term for a group of rare autoimmune diseases that cause persistent muscle inflammation, weakness, and fatigue. Currently, first-line treatment for…
  • Abstract Number: 2569 • ACR Convergence 2024

    A Novel Hyperferritinemia Screen to Aid Differentiation of Hyperinflammatory Disorders

    Hallie Carol1, Adam Mayer2, Jemy Varghese3, Zachary Martinez4, Caroline Diorio4, Paul Tsoukas5, Kate Kernan6 and Scott Canna7, 1Children's Hospital of Philadelphia, Philadelphia, 2University of Pennsylvania/Children's Hospital of Philadelphia, Philadelphia, PA, 3Division of Pediatric Rheumatology, The Children’s Hospital of Philadelphia, Philadelphia, PA, 4Division of Pediatric Oncology, The Children’s Hospital of Philadelphia, Philadelphia, PA, 5Hospital for Sick Children/University of Toronto, Toronto, ON, Canada, 6Department of Critical Care Medicine, University of Pittsburgh School of Medicine, UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA, 7Children's Hospital of Philadelphia, Philadelphia, PA

    Background/Purpose: High ferritin is an important and sensitive biomarker for the diverse and deadly group of cytokine storm syndromes grouped together under the term hemophagocytic…
  • Abstract Number: 0042 • ACR Convergence 2024

    Modulating Inflammation and Angiogenesis in an Advanced 3D Rheumatoid Arthritis Synovial Tissue Model

    Eva Philippon1, Jan Piet van Hamburg1, Lisanne van Rooijen1, Gary Sims2, Conny Van der Laken3 and Sander Tas4, 1Amsterdam UMC, Amsterdam, Netherlands, 2Immunology Biosciences, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, 3Amsterdam UMC - location VUMC, Amsterdam, Netherlands, 4Amsterdam UMC, locatie AMC, Amsterdam, Netherlands

    Background/Purpose: Rheumatoid Arthritis (RA) is a progressive and systemic autoimmune disorder characterized by chronic and destructive joint inflammation. Key features of RA include synovial cell…
  • Abstract Number: 0266 • ACR Convergence 2024

    Analysis of Gout Remission Definitions in a Randomised Controlled Trial of Colchicine Prophylaxis for People with Gout Initiating Allopurinol

    Dansoa Tabi-Amponsah1, Lisa Stamp2, Anne Horne3, Jill Drake4, Sarah Stewart5, Gregory Gamble3, Keith Petrie1 and Nicola Dalbeth3, 1The University of Auckland, Auckland, New Zealand, 2University of Otago, Christchurch, Christchurch, New Zealand, 3University of Auckland, Auckland, New Zealand, 4University of Otago, Christchurch, New Zealand, 5Auckland University of Technology, Auckland, New Zealand

    Background/Purpose: To investigate the effect of colchicine prophylaxis on gout remission when commencing urate lowering therapy (ULT), and illness perceptions of people in remission, using…
  • Abstract Number: 0567 • ACR Convergence 2024

    Alteration of JAK-STAT Signaling in an Axial Spondyloarthritispatient with TYK2 Variants

    Pankaj Sharma1, Fatemeh Navid1, Norman Watts1, Stephen Brooks2 and Robert Colbert2, 1National Institutes of Health, Bethesda, MD, 2NIH/NIAMS, Bethesda, MD

    Background/Purpose: Tyrosine kinase 2 (TYK2) is a member of the Janus kinase family that associates with the cytoplasmic domain of type I/II cytokine receptors and…
  • « Previous Page
  • 1
  • …
  • 4
  • 5
  • 6
  • 7
  • 8
  • …
  • 58
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology